Michal Shteinberg
Overview
Explore the profile of Michal Shteinberg including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
118
Citations
1557
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Chalmers J, Mall M, Chotirmall S, ODonnell A, Flume P, Hasegawa N, et al.
Eur Respir J
. 2024 Oct;
65(1).
PMID: 39467608
Persistent neutrophilic inflammation is a central feature in both the pathogenesis and progression of bronchiectasis. Neutrophils release neutrophil serine proteases (NSPs), such as neutrophil elastase (NE), cathepsin G and proteinase...
12.
Pollock J, Pollock J, Goeminne P, Goeminne P, Aliberti S, Aliberti S, et al.
Chest
. 2024 Oct;
PMID: 39461553
Background: Aspergillus species cause diverse clinical manifestations in bronchiectasis including allergic bronchopulmonary aspergillosis (ABPA), Aspergillus sensitization (AS), and raised IgG indicating exposure to, or infection with, Aspergillus. Research Question: What...
13.
Mall M, Davies J, Donaldson S, Jain R, Chalmers J, Shteinberg M
Eur Respir Rev
. 2024 Sep;
33(173).
PMID: 39293854
Chronic airway inflammation is a central feature in the pathogenesis of bronchiectasis (BE), which can be caused by cystic fibrosis (CFBE; hereafter referred to as CF lung disease) and non-CF-related...
14.
Haworth C, Shteinberg M, Winthrop K, Barker A, Blasi F, Dimakou K, et al.
Lancet Respir Med
. 2024 Sep;
12(10):787-798.
PMID: 39270696
Background: Chronic lung infection with Pseudomonas aeruginosa is associated with increased exacerbations and mortality in people with bronchiectasis. The PROMIS-I and PROMIS-II trials investigated the efficacy and safety of 12-months...
15.
Chalmers J, Shteinberg M, Mall M, ODonnell A, Watz H, Gupta A, et al.
Eur Respir J
. 2024 Sep;
65(1).
PMID: 39255990
Background: Bronchiectasis is characterised by uncontrolled neutrophil serine protease (NSP) activity. Cathepsin C (CatC; dipeptidyl peptidase 1) activates NSPs during neutrophil maturation. CatC inhibitors can potentially reduce neutrophil-mediated lung damage....
16.
Chalmers J, Mall M, McShane P, Nielsen K, Shteinberg M, Sullivan S, et al.
Eur Respir Rev
. 2024 Sep;
33(173).
PMID: 39231597
Background: The overall burden of bronchiectasis on patients and healthcare systems has not been comprehensively described. Here, we present the findings of a systematic literature review that assessed the clinical...
17.
Yaacoby-Bianu K, Dagan A, Cohen-Cymberknoh M, Tsviban L, Gur M, Golan-Tripto I, et al.
Ann Am Thorac Soc
. 2024 Jul;
21(11):1620-1623.
PMID: 39052004
No abstract available.
18.
Long M, Chotirmall S, Shteinberg M, Chalmers J
Lancet Respir Med
. 2024 Jul;
12(11):901-914.
PMID: 38971168
Bronchiectasis is understood to be the result of a complex interaction between infection, impaired mucociliary clearance, inflammation, and lung damage. Current therapeutic approaches to bronchiectasis are heavily focused on management...
19.
Marchant J, Shteinberg M, Chang A
Am J Respir Crit Care Med
. 2024 Jul;
210(1):4-5.
PMID: 38949498
No abstract available.
20.
Spinou A, Almagro M, Harris B, Boyd J, Berg T, Herrero-Cortina B, et al.
Eur Respir J
. 2024 Jun;
64(1).
PMID: 38843909
No abstract available.